Search clinical trials for: BMS-214662

Total 3179 results

Active Biotech AB

Active, not recruiting

A Study of Laquinimod Eye-drops in Healthy Participants

Eye Diseases

Austria
Yale University
National Cancer Institute (NCI)

Terminated

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

Cancer Head Neck | Metastatic Cancer | Metastatic Lung Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

France, United States, Spain, Australia, Italy, Switzerland, United Kingdom
Bluedrop Medical Limited

Recruiting

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration (MASTER)

Diabetic Foot

United States
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Taiwan, Japan, Brazil, Colombia, Germany, Poland, Puerto Rico, China, Mexico, Argentina, France, Chile, Australia, India, Spain, United Kingdom, Romania, Ireland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
R-Pharm

Completed

Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of, Taiwan, Japan, Singapore, Hong Kong
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Terminated

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Alzheimer's Disease

Sweden, United States, Canada, Denmark, France, Finland
Bristol-Myers Squibb

Terminated

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Non Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Alzheimer's Disease
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Allyx Therapeutics
Yale University; National Institute on Aging (NIA)

Recruiting

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Alzheimer's Disease

United States
Bristol-Myers Squibb
Celgene

Completed

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Healthy Volunteers

United States
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Aegerion Pharmaceuticals, Inc.
FDA Office of Orphan Products Development

Completed

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
InspireMD

Withdrawn

OCT Study of the MGuard Prime Stent in Patients With Heart Attacks (MASTER-OCT)

ST Segment Elevated Myocardial Infarction

United Kingdom
Aegerion Pharmaceuticals, Inc.
University of Pennsylvania; Doris Duke Charitable Foundation

Completed

Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor

Homozygous Familial Hypercholesterolemia

United States
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Broad Solid Tumor

United States, Argentina, Australia, Canada, Chile, Japan, Romania, Singapore
MedSIR
Medical University of Vienna

Not yet recruiting

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (REPOSE)

NSCLC | Brain Metastases | ROS1 Gene Rearrangement
Celgene

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

Healthy Volunteers

United States
Celgene

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Healthy Volunteers

Belgium
Bristol-Myers Squibb
Exelixis

Terminated

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Metastatic Cancer | Advanced Solid Cancers

United States, Canada, France
Bristol-Myers Squibb

Completed

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (STANDUP AHF)

Heart Failure

France, Germany, Japan, Spain, United States, Argentina, Poland, Italy, Czechia, Greece, Netherlands, Canada, United Kingdom
Aegerion Pharmaceuticals, Inc.

Completed

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
InspireMD

Completed

Safety and Efficacy Study of MGuard Stent After a Heart Attack (MASTER)

Myocardial Infarction

Poland, South Africa
Bristol-Myers Squibb

Completed

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Healthy Participants

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Gastric Adenocarcinoma | Esophagogastric Cancer | Gastroesophageal Junction Adenocarcinoma | Esophagus Cancer | Gastroesophageal Junction Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Healthy Subjects and Atopic Dermatitis Subjects

United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Belgium, Germany, Israel, Poland, Spain, Turkey, Australia, Chile, France
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
M.D. Anderson Cancer Center

Active, not recruiting

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic Cavity

United States
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Advanced Cancer

Italy, Australia, United States, Spain, Romania, Argentina, Canada, Chile, Finland, Germany, Poland
Bristol-Myers Squibb

Terminated

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Advanced Cancer

United States
Bristol-Myers Squibb

Completed

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Terminated

Study of BMS-663513 in Patients With Advanced Cancer

Tumors

United States, Canada, France
Bristol-Myers Squibb

Completed

Multiple Dose Japanese Bridging Study

Alzheimer Disease

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

Taiwan, Korea, Republic of, United States, Italy, South Africa, Belgium, Argentina, Israel, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more

Search clinical trials for: BMS-214662

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations